BMS, bluebird bio bag Abecma FDA approval for multiple myeloma in adults
(adsbygoogle = window.adsbygoogle || []).push({}); Abecma FDA approval : Bristol Myers Squibb (BMS) and bluebird bio have secured approval from the US Food and Drug Administration (FDA) for Abecma More...
FDA accepts Airway’s IND for AT-100 for bronchopulmonary dysplasia treatment in preterm infants
Bronchopulmonary dysplasia treatment : Airway Therapeutics said that the US Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application for developing AT-100 (rhSP-D) as a preventive More...
Anixa Biosciences files IND with FDA for ovarian cancer CAR-T therapy
Anixa Biosciences said that it has filed an investigational new drug (IND) application for its ovarian cancer CAR-T therapy with the US Food and Drug Administration (FDA). The ovarian cancer CAR-T therapy was invented More...
Precigen gets FDA orphan drug status for PRGN-2012 in RRP
Precigen has secured orphan drug designation (ODD) for PRGN-2012 from the US Food and Drug Administration (FDA) in recurrent respiratory papillomatosis (RRP). PRGN-2012 is an investigational off-the-shelf (OTS) More...
Cytocom gets FDA nod for phase 2 trial of Covid drug candidate CYTO-205
Cytocom has secured clearance from the US Food and Drug Administration (FDA) to undertake a phase 2 clinical trial of CYTO-205 for the treatment of Covid-19. The company’s investigational new drug (IND) application More...
J&J Ad26.COV2.S COVID-19 vaccine gets FDA emergency use authorization
Johnson & Johnson (J&J) said that the US Food and Drug Administration (FDA) has given emergency use authorization (EUA) for Ad26.COV2.S, a single-dose COVID-19 vaccine developed by its subsidiary Janssen More...
G1 Therapeutics gets Cosela FDA approval to reduce chemotherapy-induced bone marrow suppression
G1 Therapeutics has bagged approval for Cosela (trilaciclib) from the US Food and Drug Administration (FDA) for reducing bone marrow suppression caused by chemotherapy. Cosela FDA approval is for its use in cutting More...
Targovax gets FDA fast track status for ONCOS-102 in malignant pleural mesothelioma
Targovax, a Norwegian immune-oncology company, said that its lead candidate ONCOS-102 has secured the fast track designation from the US Food and Drug Administration (FDA) for malignant pleural mesothelioma. The More...
G1 Therapeutics gets Cosela FDA approval to reduce chemotherapy-induced bone marrow suppression
G1 Therapeutics has bagged approval for Cosela (trilaciclib) from the US Food and Drug Administration (FDA) for reducing bone marrow suppression caused by chemotherapy. Cosela FDA approval is for its use in cutting More...
Targovax gets FDA fast track status for ONCOS-102 in malignant pleural mesothelioma
Targovax, a Norwegian immune-oncology company, said that its lead candidate ONCOS-102 has secured the fast track designation from the US Food and Drug Administration (FDA) for malignant pleural mesothelioma. The More...